Share on StockTwits
 

Cepheid (NASDAQ:CPHD) has been given a consensus recommendation of “Hold” by the twenty-one ratings firms that are presently covering the stock, Analyst Ratings Network.com reports. One analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation and six have given a buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $48.73.

A number of analysts have recently weighed in on CPHD shares. Analysts at Jefferies Group raised their price target on shares of Cepheid from $36.00 to $43.00 in a research note on Friday, January 31st. Separately, analysts at Raymond James raised their price target on shares of Cepheid from $50.00 to $57.00 in a research note on Friday, January 31st. Finally, analysts at Oppenheimer raised their price target on shares of Cepheid from $43.00 to $54.00 in a research note on Friday, January 31st.

Cepheid (NASDAQ:CPHD) traded down 0.62% during mid-day trading on Wednesday, hitting $54.47. The stock had a trading volume of 147,017 shares. Cepheid has a one year low of $30.95 and a one year high of $55.48. The stock has a 50-day moving average of $49.44 and a 200-day moving average of $42.92. The company’s market cap is $3.716 billion.

Cepheid (NASDAQ:CPHD) last announced its earnings results on Friday, January 31st. The company reported ($0.15) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.11) by $0.04. The company had revenue of $113.30 million for the quarter, compared to the consensus estimate of $102.17 million. On average, analysts predict that Cepheid will post $-0.24 earnings per share for the current fiscal year.

Cepheid is a molecular diagnostics company that develops, manufactures and markets fully-integrated systems for testing in the Clinical market, as well as for application in its legacy Non-Clinical market.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.